General description
A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits human breast cancer, prostate adenocarcinoma, and ovarian carcinoma cell proliferation. Inhibits angiogenesis as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.
A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits proliferation in cell lines of human breast cancer, prostate adenocarcinoma, and ovarian carcinoma. Inhibits angiogenesis, as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Active in the prevention and treatment of a variety of neoplasms in animals.
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Formelli, F., et al. 1996. FASEB J. 10, 1014.
Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.
Delia, D., et al. 1993. Cancer Res. 53, 6036.
Pienta, K.J., et al. 1993. Cancer Res. 53, 224.
Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.
McCarthy, D.J., et al. 1987. Cancer Res.47, 5014.
Moon, R.C., et al. 1979. Cancer Res.39, 1339.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51283930
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 390900-5MG
